dismiss

Clean Sweep Live Auction on Wed. February 27th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
Advertisement

 

advertisement

 

Molecular Imaging Homepage

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Dennis Durmis MITA names chair of board of directors

Researchers find new PET tracer that better detects melanoma than 18F-FDG 18F-P3BZA could become the new gold standard

RadioMedix scores $2 million contract for Targeted Alpha-emitter therapy Treatment for neuroendocrine tumors

FDA clears United Imaging's total-body PET scanner Creating 3D images of entire human body in 15-30 seconds

FDA clears MIM SurePlan molecular radiotherapy software Can measure the absorbed dose from MRT for individual patients

Rob Beanlands ASNC names president for 2019

Former South African nuclear executives to appeal suspensions in court Involves monthslong shutdown of NTP Radioisotopes medical isotope plant

FDA grants Fast Track designation to 64-Cu-Dotatate Used in PET diagnostic exams for suspected neuroendocrine tumors

Editorial takes aim at NRC efforts to lower the bar for nuclear medicine providers 'The NRC has abdicated its role as a protection agency for patients' say authors

Cerveau Technologies is expanding its
production network for greater access
to research on the impact of a novel
imaging agent for neurodegenerative
diseases such as Alzheimer's disease

Cerveau Technologies to expand production network for research on novel tau imaging agent

by John R. Fischer , Staff Reporter
Cerveau Technologies Inc. is setting up camp in six new places throughout the U.S. thanks to a growing interest in a developmental and investigational tau imaging agent.

The Boston-based enterprise is expanding its production network to enhance access and opportunities in research for [18F]MK-6240, a novel contrast agent utilized in PET scans to assess the status and progression of neurofibrillary tangles (NFTs) within the brain as part of several neurodegenerative conditions such as Alzheimer’s disease.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“Cerveau is focused on increasing access to the transformative technologies that we believe have the potential to advance brain health,” Rick Hiatt, president and chief executive officer of Cerveau Technologies, said in a statement.

NFTs are composed of aggregated tau protein, the hallmarks of Alzheimer’s and other forms of dementia.

Consisting of 10 production sites throughout the U.S., Canada, Australia and Belgium, Cerveau has qualified six additional ones over the last few weeks in Hayward, California; Houston, Texas; Phoenix, Arizona; and Birmingham, Alabama, as well as at John Hopkins University in Baltimore, Maryland and Columbia University in New York City.

In addition, twenty other sites are undergoing capital expansion, technology transfer and startup processes to provide greater support to a variety of research and therapy clinical trial initiatives worldwide. Their locations include one in Canada, three in the U.S., four in Japan, four in Australia, four in Europe and four in China.

The growth of its production network, according to Hiatt, will support imaging biomarkers licensed by Cerveau and its partners for research and development.

“This expansion of the biomarker production network underscores our commitment to the broader scientific research community and our support of industry’s initiatives to combat neurodegenerative disorders,” he said.

Cerveau Technologies formed a number of partnerships this year to promote research for [18F]MK-6240, including one with the Kobe City Hospital Organization in Japan; another with Massachusetts General Hospital (MGH); and one with the University of Pittsburgh.

Hiatt did not respond for comment.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED